6533b853fe1ef96bd12ac0d3

RESEARCH PRODUCT

Late onset and pregnancy-induced congenital thrombotic thrombocytopenic purpura

Bernhard LämmleTanja FalterJ. A. Kremer HovingaH.-g. FüllemannKarl J. LacknerInge Scharrer

subject

Genetic Markersmedicine.medical_specialtyPediatricsmedicine.medical_treatmentSplenectomyThrombotic thrombocytopenic purpuraADAMTS13 ProteinLate onsetCongenital Thrombotic Thrombocytopenic Purpura030204 cardiovascular system & hematologyAbortionYoung Adult03 medical and health sciences0302 clinical medicinePregnancyhemic and lymphatic diseasesHumansMedicineGenetic Testing610 Medicine & healthPregnancyPurpura Thrombotic Thrombocytopenicbusiness.industryPregnancy Complications HematologicHematologymedicine.diseaseADAMTS13SurgeryADAM Proteins030220 oncology & carcinogenesisGestationFemalebusiness

description

SummaryWe report on our patient (case 2) who experienced a first acute episode of thrombotic thrombocytopenic purpura (TTP) at the age of 19 years during her first pregnancy in 1976 which ended in a spontaneous abortion in the 30th gestational week. Treatment with red blood cell concentrates was implemented and splenectomy was performed. After having suffered from several TTP episodes in 1977, possibly mitigated by acetylsalicylic acid therapy, an interruption and sterilization were performed in 1980 in her second pregnancy thereby avoiding another disease flare-up. Her elder sister (case 1) had been diagnosed with TTP in 1974, also during her first pregnancy. She died in 1977 during her second pregnancy from a second acute TTP episode. Diagnosis: In 2013 a severe ADAMTS13 deficiency of <10% without detectable ADAMTS13 inhibitor was repeatedly found. Investigation of the ADAMTS13 gene showed that the severe ADAMTS13 deficiency was caused by compound heterozygous ADAMTS13 mutations: a premature stop codon in exon 2 (p.Q44X), and a missense mutation in exon 24 (p.R1060W) associated with low but measurable ADAMTS13 activity. Conclusion: Genetic analysis of the ADAMTS13 gene is important in TTP patients of all ages if an ADAMTS13 inhibitor has been excluded.

https://doi.org/10.5482/hamo-14-03-0023